uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Science for Life Laboratory, SciLifeLab.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Science for Life Laboratory, SciLifeLab.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Science for Life Laboratory, SciLifeLab.
2016 (English)In: Immunity, Inflammation and Disease, ISSN 1750-743X, E-ISSN 2253-1556, Vol. 8, no 12, 1355-1361 p.Article in journal, Editorial material (Refereed) Published
Abstract [en]

Adoptive transfer of patient-derived T-cells engineered with a chimeric antigen receptor (CAR) targeting the pan-B-cell marker CD19 has led to complete remission in patients with B-cell leukemias while response rates are more modest for B-cell lymphomas. This can be attributed to the fact that the semi-solid structure of lymphomas impedes T-cell infiltration and that the immune suppressive microenvironment within these tumors dampens the effect of CAR T-cells. These obstacles are even more pronounced for solid tumors where dense and often highly immunosuppressive structures are found. This article focuses on different aspects of how to improve CAR T-cells for solid tumors, primarily by decreasing their sensitivity to the harsh tumor microenvironment, by altering the immunosuppressive microenvironment inside tumors and by inducing bystander immunity.

Place, publisher, year, edition, pages
2016. Vol. 8, no 12, 1355-1361 p.
Keyword [en]
bystander immunity, CAR T-cells, immune suppression
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:uu:diva-316211DOI: 10.2217/imt-2016-0125ISI: 000391864000002PubMedID: 28000533OAI: oai:DiVA.org:uu-316211DiVA: diva2:1077437
Available from: 2017-02-27 Created: 2017-02-27 Last updated: 2017-02-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jin, ChuanYu, DiEssand, Magnus
By organisation
Clinical ImmunologyScience for Life Laboratory, SciLifeLab
In the same journal
Immunity, Inflammation and Disease
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 193 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf